Basedow’s disease and Graves’ disease are two names for the same condition: an autoimmune disorder in which the body’s immune system attacks the thyroid gland and forces it to overproduce hormones. The name you hear depends mostly on geography. In much of continental Europe, the condition is called Basedow’s disease (or Morbus Basedow), after the German physician Carl Adolph von Basedow, while in English-speaking countries and much of Asia it goes by Graves’ disease, after the Irish doctor Robert Graves. Regardless of the label, the condition is the leading cause of hyperthyroidism in adults, and its effects reach well beyond the thyroid itself.
Why the Disease Has Two Names
Carl Adolph von Basedow published his landmark description of the condition in 1840, documenting a triad of symptoms he observed in patients near Merseburg, Germany: bulging eyes (exophthalmos), an enlarged thyroid (goiter), and a racing heart (palpitations). This cluster became known as the Merseburg Triad.1PubMed. Carl Adolph von Basedow–on the 200th anniversary of his birth Robert Graves had actually described similar findings a few years earlier, in 1835, but Basedow’s account was more detailed and circulated widely through German-language medical literature. The result is a persistent naming split across borders. In clinical papers you will sometimes see “Graves’ disease (GD)” with Basedow referenced in parentheses, or the reverse, but the underlying biology is identical.
One interesting footnote: the classic Merseburg Triad of goiter, thyrotoxicosis, and eye disease may not be as common a presentation as it once was. A Brazilian retrospective study spanning 30 years found that the clinical picture of the disease has shifted over time, with some components of the triad appearing less frequently at initial diagnosis than they did decades ago.2PubMed Central. The change in the clinical presentation of Graves’ disease: a 30 years retrospective survey in an academic Brazilian tertiary center This likely reflects earlier detection through blood tests rather than waiting for visible eye or neck changes.
What Goes Wrong Immunologically
The core problem in Basedow’s disease is a case of mistaken identity by the immune system. Normally, thyroid-stimulating hormone (TSH) travels from the pituitary gland to TSH receptors on thyroid cells, telling the gland how much hormone to make. In Basedow’s disease, the immune system produces antibodies that latch onto those same receptors and mimic TSH, driving the thyroid to produce hormones non-stop. These stimulating TSH receptor antibodies are the hallmark of the disease.3PubMed Central. TSH receptor autoantibodies
The picture is more nuanced than just one type of antibody, though. Researchers have identified at least three varieties of TSH receptor antibodies in patients: stimulating antibodies that rev up hormone production, blocking antibodies that can actually suppress the gland, and cleavage-region antibodies with mixed effects ranging from thyroid cell growth to cell death.4PubMed Central. Graves’ Disease Mechanisms: The Role of Stimulating, Blocking, and Cleavage Region TSH Receptor Antibodies This explains why some patients swing between overactive and underactive thyroid states, and why the disease can behave unpredictably over time.
Genetics and Environmental Triggers
Basedow’s disease runs in families, but it does not follow a simple one-gene pattern. More than 80 genetic regions have been linked to susceptibility so far, with variants in genes like HLA, CTLA4, and PTPN22 having the strongest individual effects.5PubMed Central. The genetics of Graves’ disease Having a close relative with the disease raises your risk, but many people carry susceptibility genes without ever developing the condition. Something in the environment has to tip the balance.
The list of potential environmental triggers is long: iodine intake, infections, psychological stress, vitamin D deficiency, selenium levels, and smoking have all been studied.6PubMed. Etiopathogenesis of Basedow’s disease. Trends and current aspects Smoking deserves special mention because its relationship with the disease is counterintuitive. Active smokers are at higher risk of developing both Basedow’s disease and its eye complications. But quitting smoking also carries immune risks: smoking cessation has been linked to a roughly sevenfold higher chance of developing autoimmune hypothyroidism, especially in the first year, possibly because sudden changes in oxidative stress and iodine delivery to the thyroid provoke a fresh immune response.7PubMed Central. Quitting smoking as a probable trigger for new-onset hypothyroidism after successful medical treatment of Graves’ disease: case report That does not mean you should keep smoking to avoid thyroid problems. It means clinicians need to watch thyroid function closely in patients who quit during or after treatment.
How the Disease Affects the Eyes
The bulging eyes that Basedow originally described remain one of the most recognizable features of the disease, now called thyroid eye disease (TED) or Graves’ orbitopathy. The problem is not in the eyeball itself but in the tissue behind it. Immune cells attack fibroblasts in the eye socket, causing them to swell and produce excess connective tissue. This pushes the eyeball forward, restricts eye movement, and can threaten vision in severe cases.
Research has shown that these orbital fibroblasts express high levels of both TSH receptors and insulin-like growth factor-I (IGF-I) receptors, and the interaction between these two receptors appears to drive much of the inflammation and tissue expansion.8PubMed. TSHR-IGF-IR complex drives orbital fibroblast misbehavior in thyroid eye disease This finding opened the door for teprotumumab, a medication that blocks the IGF-I receptor. A meta-analysis concluded that teprotumumab can safely and effectively treat active thyroid eye disease, and it represents a genuine shift in how the eye complications are managed.9PubMed Central. Teprotumumab for treating active thyroid eye disease: A meta-analysis Before teprotumumab, treatment options for moderate-to-severe eye disease were largely limited to steroids, radiation, and surgical decompression.
Skin and Cardiovascular Complications
Beyond the thyroid and eyes, Basedow’s disease occasionally attacks the skin, usually on the shins. This condition, called pretibial myxedema or thyroid dermopathy, causes thickened, waxy, discolored patches. The most common form is nonpitting edema, and the pretibial area is involved in the vast majority of cases.10The Journal of Clinical Endocrinology & Metabolism. Dermopathy of Graves’ Disease (Pretibial Myxedema): Long-Term Outcome The lesions are typically more of a cosmetic concern than a medical one, though advanced forms can cause significant swelling. Almost all patients with thyroid dermopathy also have severe eye disease and very high levels of TSH receptor antibodies, suggesting a shared autoimmune mechanism driven by TSH receptors in the connective tissue.11PubMed. Pretibial myxedema: pathophysiology and treatment options Topical corticosteroids are the standard first-line treatment.12PubMed Central. Pretibial myxedema in Grave’s disease: A case report and treatment review of the literature
The heart is another organ that takes a hit. Excess thyroid hormone creates a hyperdynamic circulation, pushing the heart to beat faster and harder. In patients with preexisting heart disease, this added workload can tip the balance toward heart failure, angina, or atrial fibrillation.13Archives of Internal Medicine. Hyperthyroidism and Risk of Atrial Fibrillation or Flutter: A Population-Based Study A study focused specifically on Graves’ disease found that overt hyperthyroidism, older age, and male sex were independent risk factors for developing atrial fibrillation, and that patients who did develop it faced dramatically higher rates of cardiac hospitalization and mortality.14PubMed. Incidence, Risk Factors, and Outcomes of Incident Atrial Fibrillation in Patients With Graves Disease This is one of the clearest reasons not to let hyperthyroidism linger untreated.
Psychiatric and Neurological Effects
People with untreated Basedow’s disease often experience agitation, irritability, anxiety, and mood swings. These are so common they are considered typical features of thyrotoxicosis. Less commonly, the disease can trigger frank psychosis. Case reports document patients presenting with hypomania and paranoia severe enough to land them in acute psychiatric care before anyone thought to check their thyroid.15BMJ Case Reports. Graves’ disease presenting with hypomania and paranoia to the acute psychiatry service The important clinical lesson is that unexplained psychiatric symptoms, especially new-onset mania or psychosis without a psychiatric history, warrant thyroid function testing.
Even after successful treatment, some patients report lingering mental fatigue and cognitive complaints. A study found that about 38% of treated Graves’ disease patients reported residual mental fatigue, with roughly a quarter of those also experiencing depression. Interestingly, formal cognitive testing did not reveal measurable deficits, suggesting a disconnect between how patients feel and what tests detect.16PubMed Central. The relationship between mental fatigue, depression, and cognition in Graves’ disease This is an area where the science has not caught up with patient experience, and many people feel frustratingly dismissed when they report brain fog after their lab numbers have normalized.
Diagnosis
Diagnosing Basedow’s disease usually starts with blood tests showing suppressed TSH alongside elevated thyroid hormones. But those findings only confirm hyperthyroidism, not its cause. The test that pins it specifically to Basedow’s disease is the TSH receptor antibody (TRAb) assay. In one clinical study, TRAb testing distinguished Graves’ disease from non-Graves’ hyperthyroidism with high accuracy, achieving roughly 91% sensitivity and 90% specificity at an optimized threshold.17PubMed Central. Utility of TSH Receptor Antibodies in the Differential Diagnosis of Hyperthyroidism in Clinical Practice A radioactive iodine uptake scan can also help, showing diffuse uptake across the entire gland rather than the patchy or focal uptake seen with toxic nodules.
Treatment Options
There are three established ways to treat Basedow’s disease: antithyroid drugs, radioactive iodine, and surgery. Which one gets recommended depends on the patient’s age, the severity of symptoms, whether eye disease is present, and regional practice patterns. In much of Europe and Japan, antithyroid medication tends to be the first choice. In the United States, radioactive iodine has historically been preferred, though this has been shifting.
Antithyroid Medications
Methimazole (known as thiamazole in many countries) and propylthiouracil (PTU) work by blocking the production of thyroid hormones. Methimazole is generally preferred because it has fewer side effects. A direct comparison found that liver-related side effects were more common with PTU, and methimazole at lower doses caused fewer problems than at higher doses.18The Journal of Clinical Endocrinology & Metabolism. Comparison of Methimazole and Propylthiouracil in Patients with Hyperthyroidism Caused by Graves’ Disease Common side effects of methimazole include itching, hives, and joint pain. Rarer but serious complications include a dangerous drop in white blood cells (neutropenia) and, very rarely, Stevens-Johnson syndrome.19PubMed Central. Adverse Events Associated with Methimazole Therapy of Graves’ Disease in Children Patients on these medications are typically told to seek immediate medical attention if they develop a fever or sore throat, which could signal neutropenia.
Radioactive Iodine and Surgery
Radioactive iodine (RAI) delivers targeted radiation to thyroid cells, gradually shrinking the gland and reducing hormone output. It is effective but comes with trade-offs. Most patients eventually become hypothyroid and need lifelong thyroid hormone replacement. There is also a small risk of triggering or worsening thyroid eye disease: one study found that about 5% of patients developed eye complications after RAI, mostly those who had risk factors and did not receive preventive steroid treatment.20PubMed Central. Radioactive iodine treatment for Graves’ hyperthyroidism: incidence of Graves orbitopathy
Total thyroidectomy (surgical removal of the gland) is the most definitive option. It eliminates the thyroid tissue entirely, which means guaranteed hypothyroidism requiring daily medication but also no chance of relapse. The surgery carries procedural risks: a large database study found that Graves’ disease patients undergoing total thyroidectomy had higher rates of complications compared to patients having thyroidectomy for other reasons, including more frequent readmissions for low calcium (hypocalcemia) and reoperations for bleeding.21PubMed. Postoperative Complications After Total Thyroidectomy for Patients With Graves’ Disease The higher complication rate is partly because the overactive, blood-vessel-rich gland in Graves’ disease is technically harder to remove. That said, another study comparing Graves’ thyroidectomies with surgeries for benign goiters found no significant difference in rates of vocal cord nerve injury, permanent hypoparathyroidism, or hemorrhagic complications, with only a more frequent temporary calcium dip on day one standing out.22PubMed. Postoperative complications in total thyroidectomy for Graves disease: comparison with multinodular benign goiter surgery These slightly conflicting findings likely reflect differences in study size and surgical experience.
Remission and What Predicts It
For patients treated with antithyroid drugs, the big question is whether the disease will come back after the medication is stopped. Remission rates are modest, and relapse is common. A study identifying predictors of long-term remission found that being female, not smoking, having no eye disease, and taking antithyroid drugs for more than 24 months were all associated with longer remission. In a multiple regression analysis, only a treatment course exceeding 24 months independently predicted lasting remission.23PubMed. Predictors of long-term remission in patients with Graves’ disease: a single center experience
A multicenter study looking at recurrence risk found that older age and higher initial free T4 levels each independently raised the odds of relapse, with roughly a 31% increase in recurrence risk per additional decade of age and a 65% increase for every 2.0 ng/dL rise in baseline free T4.24PubMed Central. A Predictive Model for Graves’ Disease Recurrence After Antithyroid Drug Therapy: A Retrospective Multicenter Cohort Study In pediatric patients, remission rates with antithyroid drugs alone appear even lower. A study of 47 children with Graves’ disease found that only about 4% achieved remission on medication, with most eventually needing definitive treatment.25PubMed Central. Pediatric Graves’ disease: insights into clinical characteristics and treatment outcomes
Pregnancy and Neonatal Risks
Basedow’s disease in pregnancy requires careful management because both uncontrolled hyperthyroidism and the medications used to treat it can harm the fetus. The goal is to keep thyroid hormone levels in the upper range of normal throughout pregnancy, which minimizes risks to both mother and baby.26PubMed Central. Graves’ hyperthyroidism in pregnancy: a clinical review PTU is generally preferred over methimazole in the first trimester because methimazole has been associated with rare birth defects.
A lesser-known concern is that TSH receptor antibodies can cross the placenta and affect the fetus, even in mothers who have already been treated for Basedow’s disease and are currently in remission. Case reports have documented neonatal Graves’ disease in babies born to mothers with high antibody levels despite having undergone thyroid surgery or radioactive iodine years earlier.27Journal of Clinical and Translational Endocrinology: Case Reports. Neonatal Graves’ disease from high maternal TRAB antibody levels despite definitive therapy A systematic review recommended intensive fetal monitoring when maternal TRAb concentrations exceed roughly 3.7 times the upper limit of normal, though the authors cautioned that this threshold is based on limited evidence.28PubMed. Maternal Thyrotropin Receptor Antibody Concentration and the Risk of Fetal and Neonatal Thyrotoxicosis: A Systematic Review
Thyroid Storm
The most dangerous acute complication of Basedow’s disease is thyroid storm, a life-threatening surge of thyroid hormone activity. It can be triggered by infection, surgery, stopping medication abruptly, or sometimes for no identifiable reason. Key features include high fever (often above 38.5°C), a racing heart out of proportion to the fever, confusion or altered consciousness, and gastrointestinal symptoms like nausea, vomiting, and diarrhea.29The Journal of Clinical Endocrinology & Metabolism. Approach to the patient with thyroid storm Without treatment, mortality from thyroid storm ranges from 80% to 100%. Even with aggressive treatment, it remains between 10% and 50%.30PubMed Central. Acute and emergency care for thyrotoxicosis and thyroid storm Thyroid storm is rare, but its severity is why doctors insist on controlling hyperthyroidism before elective surgery and why abruptly stopping antithyroid medication is discouraged.
Selenium and Emerging Research
Selenium has attracted attention as a potential add-on treatment, especially for the eye complications of Basedow’s disease. A randomized trial published in the New England Journal of Medicine found that selenium supplementation in patients with mild Graves’ orbitopathy improved quality of life, reduced eye involvement, and slowed disease progression compared to placebo at six months, with benefits confirmed at twelve months and no notable side effects.31PubMed. Selenium and the course of mild Graves’ orbitopathy Based on this trial, selenium is now commonly recommended for patients with mild eye disease, though no data exist for more severe forms.32PubMed Central. Selenium in the Treatment of Graves’ Hyperthyroidism and Eye Disease
For hyperthyroidism itself (as opposed to the eye disease), a meta-analysis found that selenium supplementation may help patients return to normal thyroid function faster when used alongside antithyroid drugs.33PubMed Central. Effects of Selenium Supplementation on Graves’ Disease: A Systematic Review and Meta-Analysis The evidence here is more tentative, and selenium is not considered a standalone treatment. It is worth noting that selenium can be toxic at high doses, so supplementation should be discussed with a doctor rather than self-prescribed.
A newer line of research is examining the role of gut bacteria. Studies have found correlations between altered gut microbiota and Graves’ disease, with the hypothesis that an imbalanced microbial community may contribute to the breakdown of immune tolerance that kicks off the disease.34PubMed Central. Gut Microbiome and the Role of Metabolites in the Study of Graves’ Disease This research is still early-stage and correlational, but it reflects a broader trend in autoimmune disease research toward understanding how the immune system, the gut, and the thyroid influence each other. Whether microbiome-targeted therapies could someday prevent or treat Basedow’s disease remains speculative.